Gilead Sciences (GILD) is back in focus after Trodelvy secured U.S. FDA approval and European marketing authorization as a first-line treatment for unresectable or metastatic triple-negative breast cancer, expanding its role in breast cancer care.

At a share price of $127.88, Gilead Sciences has seen a 1-day share price return of 3.26% and a 7-day share price return of 2.41%. The 30-day and 90-day share price returns are down 4.87% and 8.24% respectively. However, the 1-year total shareholder return of 18.35% and 5-year total shareholder return of 121.48% indicate that longer term holders have experienced materially better outcomes as Trodelvy approvals and other pipeline news reset market expectations around growth and risk.

If you are interested in how other healthcare and biotech stories are shaping up, this is a good moment to scan for oncology focused opportunities with the 40 healthcare AI stocks

With Trodelvy winning first line approvals on both sides of the Atlantic and Gilead Sciences stock up strongly over 1 year, the key question now is simple: is there still mispricing here, or is the market already factoring in the next stage of growth?

Most Popular Narrative: 40% Undervalued

According to the most followed narrative on Gilead Sciences, a fair value of $128.38 sits just above the last close at $127.88, suggesting the recent Trodelvy approval sits within a broader multi year story rather than a one day reaction.

Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with: High-probability growth drivers (lenacapavir, Trodelvy). High-upside optionality (cell therapy, immunology). Temporary earnings headwinds masking long-term value creation.

The fair value in this narrative leans heavily on one core idea: higher earnings powered by a concentrated set of drugs and a richer profit mix. Curious which revenue engines, margin assumptions and future earnings multiple sit under that $128.38 figure and the view that Gilead Sciences trades at roughly a 40% discount to its long term potential.

Result: Fair Value of $128.38 (UNDERVALUED)

However, this Gilead Sciences narrative still hinges on smooth Trodelvy execution and successful integration of recent acquisitions, where clinical or earnings disappointments could quickly reset sentiment.

Another View on Gilead Sciences Valuation

The user generated memo leans on a fair value of $128.38, which sits close to Gilead Sciences' last close at $127.88. Looking at simple earnings multiples instead, Gilead Sciences trades at a P/E of 17.2x, in line with the US Biotechs industry at 17.2x but far below peer average of 48.2x and a fair ratio of 31.1x. That mix of parity to the sector, discount to peers and gap to the fair ratio frames a different question: is the risk now that expectations are too low rather than too high?

Next Steps

With the mix of optimism and caution running through this Gilead Sciences story, it is worth moving quickly from headlines to the underlying details yourself and weighing both sides of the argument, starting with the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Gilead Sciences?

Once you have formed a view on Gilead Sciences, it can be useful to broaden your watchlist with a few focused screens that highlight very different types of opportunities.

• Target stronger income potential by reviewing companies screened as 8 dividend fortresses that combine higher yields with a focus on stability.
• Hunt for value opportunities by scanning the screener containing 19 high quality undiscovered gems where solid fundamentals may not yet be fully appreciated by the market.
• Prioritize resilience by focusing on companies identified in the 69 resilient stocks with low risk scores that aim to keep risk scores in check while still offering upside potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.